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Adjuvant Chemotherapy Uptake in Non-small Cell
Lung Cancer
Tallal Younis, MBBCh, FRCP (UK),*† Turki Al-Fayea, MBBS,*† Kiran Virik, MBBS, FRACP,*†
Wojciech Morzycki, MD, FRCPC,*† and Nathalie Saint-Jacques, MSc‡
Introduction: Adjuvant chemotherapy in non-small cell lung cancer
(NSCLC) has become a new standard of care. This study examines the
uptake patterns for adjuvant chemotherapy outside of clinical trials.
Methods: A retrospective study of all patients diagnosed with
NSCLC in the year 2005 who underwent curative-intent surgery in
Nova Scotia, Canada was conducted. Logistic regression models and
discriminant function analyses were employed to identify cofactors
associated with referral to medical oncology and/or utilization of
adjuvant chemotherapy.
Results: Of 540 patients with NSCLC, 108 underwent curative-
intent surgery (67% lobectomy; 15% pneumonectomy; 19% wedge
resection) for NSCLC (39% IA; 24% IB; 25% II; 14% III). Referral
to medical oncology was observed in 44% (47 of 108) of all patients
including 73% (30 of 41) of those with stage II–III. Adjuvant
chemotherapy utilization was observed in 62% (29 of 47) of those
referred including 73% (22 of 30) of those with stage II–III. Overall,
27% (29 of 108) of all patients received adjuvant chemotherapy,
including 54% (22 of 41) of those with stage II–III. Higher uptake
was significantly associated with age (younger versus older), stage
(II/III versus I), and surgery type (pneumonectomy versus wedge).
Weaker associations were observed with other cofactors including
surgeon, health center, mean household income, and surgery-med-
ical oncologist consult timeline.
Conclusions: The uptake of adjuvant chemotherapy in patients with
resected NSCLC outside of clinical trials is low overall, but is higher
among younger patients and those with more advanced stages. These
uptake patterns may allow future planning of health resource utili-
zation and/or improvement of chemotherapy utilization rates.
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Patients undergoing curative-intent surgical resection forearly-stage breast, colorectal and lung cancers represent a
potentially curable population. For those patients with higher
risk disease, adjuvant chemotherapy has been shown to improve
overall survival.1–5 However, the overall impact of adjuvant
chemotherapy in cancer patients ultimately depends upon its
uptake in unselected patient populations outside of clinical trials.
The uptake of adjuvant chemotherapy in breast and
colorectal cancers has been previously examined.6–14 Guide-
lines currently recommend adjuvant chemotherapy for pa-
tients with node-positive or high-risk node-negative breast
cancer and for patients with stage III and possibly high-risk
stage II colorectal cancer.15,16 Approximately 30% and 50%
of patients with non metastatic breast cancer were treated
with adjuvant chemotherapy in the mid 1990s and in the year
2000, respectively.6–9 Higher uptake was associated with
younger age, more advanced stage disease, and negative hor-
mone receptor status. As well, approximately 30% of patients
with non metastatic colorectal cancer were treated with adjuvant
chemotherapy.10–14 Higher uptake was associated with younger
age, more advanced stages (e.g., 70% uptake in patients with
stage III disease) and fewer comorbidities.
A number of recent clinical studies have revealed that
adjuvant chemotherapy improves overall survival for patients
with higher risk non-small cell lung cancer (NSCLC) follow-
ing curative-intent surgical resection.17–24 Current guidelines
recommend adjuvant platinum based doublet chemotherapy
for patients with resected stage II–IIIA NSCLC, while evi-
dence is less clear for stage IB disease.25,26 The overall
survival impact of adjuvant chemotherapy, however, will
depend upon its uptake outside of these clinical trials. We
examined the uptake patterns of adjuvant chemotherapy in
NSCLC patients including; (1) the rates of referral to medical
oncology (MO) and/or utilization of adjuvant chemotherapy,
and (2) the factors associated with a higher referral to MO
and/or utilization of adjuvant chemotherapy.
PATIENTS AND METHODS
The study cohort included all patients diagnosed with
NSCLC in the year 2005 who underwent curative-intent
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surgical resection for stage I–III disease in Nova Scotia,
Canada. Patients were identified through the Nova Scotia
Cancer Registry and retrospective chart reviews at the two
health centers in Nova Scotia where thoracic surgeries are
exclusively performed: (1) the Queen Elizabeth II Health
Sciences Centre in Halifax or the (2) Cape Breton Regional
Hospital (CBRH) in Sydney.
A retrospective review was conducted to abstract pa-
tient demographics as well as disease and treatment charac-
teristics from radiologic, surgical, and pathology reports con-
tained in patient charts and the Oncology Patient Information
System (a database maintained by the Nova Scotia Cancer
Registry and the regional cancer centers). Data quality in
Oncology Patient Information System is ensured through
online system edits, routine edits, and periodic chart audits.
Dates of care events abstracted included: (i) disease detection
(Detection), (ii) definitive curative-intent surgery (Surgery),
and (iii) first MO consultation (MO Consult). Disease detec-
tion was defined as the first abnormal imaging study that
prompted a referral for surgery consultation.
Referral to MO (Referral) and adjuvant chemotherapy
treatment (Treatment) were noted. The study cohort was
divided into three groups based on Referral and Treatment
states; (A) not referred, (B) referred-not treated, and (C)
referred-treated. The rates of “Referral” (referred/resected)
and “Treatment” (treated/referred) as well as “Overall Up-
take” of adjuvant chemotherapy (treated/resected) were com-
puted. Any identified reasons for no referral or no treatment
were abstracted.
A logistic regression (LR) model with a stepwise se-
lection (p  0.05) was used to identify the primary cofactors
influencing Referral and Treatment. Cofactors were entered
into the stepwise selection analysis only if their univariate
probability of nonrandom association was 0.3. The exam-
ined cofactors included: patient sex (Sex), age at diagnosis
(Age), marital status (Marital Status), smoking history
(Smoking), lung cancer subtype (Histopathology), stage of
disease (Stage), margin status (Margin), the presence or
absence of ischemic heart disease or diabetes mellitus (Co-
morbidity), performance status (PS) based on the Eastern
Cooperative Oncology Group scale, health center where sur-
gically treated (Health Centre), type of definitive surgery
(Surgery Type), presence or absence of postoperative com-
plications (PO Complication), surgeon (Surgeon), medical
oncologist (Med Onc), distance of residence to a cancer
center derived from address at diagnosis (Distance), median
household income (MHI) in the area of patient residence,
mean level of education in the area of patient residence
(Education), and the time elapsed between Detection-Surgery
(Detection-Surgery elapsed time) and Surgery-Medical On-
cologist Consult (Surgery-MO Consult elapsed time). Time-
lines between these two care intervals were adjusted for
cofactors and expressed as calendar days.27 Underlying lung
cancer histopathologies were squamous carcinoma, adenocar-
cinoma, and other (large cell and bronchio-alveolar carcino-
mas). Mixed NSCLC-small cell lung cancers were excluded.
Aggregate census data from 1996 and 2001 were used to
compute the socio-economic factors. Variations in MO prac-
tices could not be accounted within multifactorial analyses
due to the small number of entries (5) in each factor level.
Discriminant function analysis (DFA) was used to ver-
ify the robustness of the results obtained by LR, as it is
considered preferable to stepwise LR for cofactor selection in
data sets with small sample size.28 DFA is a multivariate
statistical method that finds the linear combination (the dis-
criminant function) of attributes (cofactors) that best sepa-
rates two groups (e.g., not referred versus referred).28 An
analysis of variance was used to test for the significance of
the difference between the group centroids (means). A 2 test
with Yates’ continuity correction was used to determine the
predictive value of the discriminant function (i.e., the capac-
ity of the resulting combination of cofactors to predict either
Referral or Treatment patterns).
RESULTS
Of 540 patients who were diagnosed with NSCLC in
Nova Scotia, Canada in the year 2005, a total of 108 patients
(20%) underwent curative-intent surgical resection (lobec-
tomy 67%,; pneumonectomy 15%; wedge resection 18%) for
stage I–III disease (39% IA; 23% IB; 24% II; 14% III). Their
median age was 66 years, and 56% were males. Other
characteristics are described in Table 1.
Referral and Treatment patterns are shown in Figure 1.
After curative-intent surgery, 44% (47 of 108) of all patients
were referred to MO for consideration of adjuvant chemo-
therapy including 73% (30 of 41) of those with stage II–III
disease. Of all those referred, 62% (29 of 47) were treated
with adjuvant chemotherapy including 73% (22 of 30) of
those with stage II–III disease. Overall, adjuvant chemother-
apy was prescribed in 27% (29 of 108) of all patients after
curative-intent surgery including 54% (22 of 41) of those
with stage II–III disease. All patients received platinum-
based doublet chemotherapy including paclitaxel and carbo-
platin (23 of 29), vinorelbine and cisplatin (5 of 29) or
vinorelbine and carboplatin (1 of 29).
Physician recommendation and patient choice were the
most common identified causes for “no referral” and “no
treatment” (Table 2). Of 61 patients not referred to MO,
surgeons did not recommend referral in 64% while 5%
refused referral. Of 18 patients who were referred but not
treated, medical oncologists did not recommend treatment in
39% while 39% refused treatment. Overall, patients with
stage IA disease represented 59% (33 of 56) of all patients for
whom chemotherapy was not recommended by surgeons
and/or medical oncologists.
A number of cofactors were associated with uptake
patterns by univariate analysis (Table 3). Younger age (65
versus 65–75 versus 75 years), more advanced stage (II–III
versus IB versus IA), and more extensive surgery (pneumo-
nectomy versus lobectomy versus wedge resection) were
significant predictors of higher Referral, Treatment, and
Overall Uptake. Practice related variables, including Health
Centre and/or Surgeon, were also associated with Referral
and Overall Uptake. Socio-economic variables, including
Distance and MHI, were weakly associated with Referral;
patients living closer to cancer center (p  0.049) and in
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areas of higher MHI (p  0.049) were more likely to be
referred. There were no statistically significant associations
between uptake patterns and other cofactors including Sex,
Marital Status, Smoking, Histopathology, Margin, Comorbid-
ity, PS, PO Complication, Med Onc or Education. As well,
there were no significant associations observed between “De-
tection-Surgery” elapsed time (median 108 days) and uptake
patterns. However, an inverse association was observed be-
tween “Surgery-MO Consult” elapsed time (median 49 days)
and Treatment; referred patients who experienced shorter
versus longer wait times to MO consult (49 versus 49
days) were more likely treated (76% versus 46%, respec-
tively: p  0.039).
Referral and Treatment patterns were examined further
using both multifactorial (LR) and multivariate (DFA) anal-
yses. Based on LR, independent predictors of Referral (Table
4) were Stage (P  0.001), Age (p  0.005), Surgery Type
(p  0.005), Surgeon (P  0.03), and MHI (p  0.02).
Independent predictors of Treatment were Age (OR  2.3;
95% CI, 1.1–4.76; p  0.016) as well as Stage and Surgery
Type: none of the patients who had stage IA disease or
underwent wedge surgery were treated with adjuvant chemo-
therapy. DFA showed very similar Referral and Treatment
patterns (Figure 2). Higher likelihood of Referral was asso-
ciated with Stage (II/III versus I), Age (younger versus older),
Surgery Type (pneumonectomy versus wedge), Health Cen-
tre (CBRH versus NSCC), and MHI (higher versus lower).
Higher likelihood of Treatment was associated with Stage
(II/III versus I), Age (younger versus older), Surgery Type
(pneumonectomy versus wedge) and “Surgery-MO Consult”
FIGURE 1. Uptake patterns. Number of patients
diagnosed with Non-small Cell Lung Cancer
(NSCLC) and those who underwent surgical re-
section over 1 year in Nova Scotia, Canada are
shown (all stages or stage II–III). The circles show
numbers (n) and percentages (%) of patients ac-
cording to Referral (referred/resected), Treatment
(treated/referred) and Overall Uptake (treated/
resected).
TABLE 1. Characteristics of Study Population
Cofactors: No. (%)
Age (yr) Histopathology Surgeon
65 46 (43) Adenocarcinoma 46 (43) A 34 (32)
65–75 40 (37) Squamous 35 (32) B 26 (24)
75 22 (20) Other 27 (25) C 10 (9)
Sex Stage D 38 (35)
Male 61 (56) IA 42 (39) Surgery type
Female 47 (44) IB 25 (23) Wedge 20 (18)
Marital status II 26 (24) Lobectomy 72 (67)
Married 75 (86) IIIa 15 (14) Pneumonectomy 16 (15)
Single 12 (14) Margin PO complications
Smoking Negative 99 (97) No 69 (64)
Current 36 (35) Positive 3 (3) Yes 39 (36)
Former 55 (53) Comorbidity Med oncologist
Never 13 (12) Yes 34 (33) A 7 (16)
Education No 69 (67) B 3 (7)
Median 44 (41) PS C 2 (5)
Median 64 (59) 0–1 77 (71) D 12 (28)
MHI ($) II–III 31 (29) E 5 (12)
Low (40K) 47 (44) Health centre F 7 (16)
High (40K) 61 (56) QEII HSC 97 (90) G 7 (16)
Distance (km) CBRH 11 (10)
Near (32) 56 (52)
Far (32) 52 (48)
a Two patients underwent curative-intent surgery for stage IIIB disease, and were included in this cohort.
MHI, median household income; K, thousands; km, kilometer; PS, performance status; QEII HSC, Queen Elizabeth II
Health Sciences Centre; CBRH, Cape Breton Regional Hospital; PO Complications, postoperative complications; Med Onc,
medical oncologist.
Younis et al. Journal of Thoracic Oncology • Volume 3, Number 11, November 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer1274
elapsed time (shorter versus longer). These DFA models
correctly predicted 80% and 85% of observed Referral and
Treatment patterns, respectively. Misclassifications in Refer-
ral (Figure 2A) were mainly due to the presence of patients
with early stage disease among the referred population and
patients with advanced stage disease among the nonreferred
population. Misclassifications in Treatment (Figure 2B) were
mainly due to the presence of patients with older age and
stage IB disease among treated population and a patient living
in an area with the highest MHI among non treated popula-
tion.
DISCUSSION
Adjuvant chemotherapy has recently become a new
standard of care for patients with NSCLC after clinical trials
showed approximately 10% improvement in overall survival
for those with higher risk disease (i.e., stage II and IIIA).3–5
In this population-based study, approximately one third of the
patients who underwent curative-intent surgical resection for
NSCLC were subsequently treated with adjuvant chemother-
apy. These uptake rates may seem comparable to that in
breast or colorectal cancers.6–14 However, there are far fewer
patients who undergo curative-intent surgical resection for
NSCLC compared with other cancers as stage distribution in
lung cancer is shifted towards more advanced stages.29–32 In
this study, only 20% of the patients with NSCLC underwent
curative-intent surgical resection. Adjuvant chemotherapy
therefore, would be expected to result in a modest less than
1% improvement in the current 5-year overall survival rate of
15% in lung cancer.30–32
Our finding of a lower uptake of chemotherapy in older
patients has also been observed in studies examining other
cancers.33–35 This could reflect concerns about higher toxic-
TABLE 2. Identified Causes for “No Referral” and “No
Treatment” by Stage
Uptake Pattern Underlying Causes
Disease Stage
Total No.
of PatientsIA IB II–III
No referrala Not recommended 30 4 5 39
Refused by patient 0 2 1 3
Unknown/other 8 6 5 19
Total 38 12 11 61
No treatmentb Not recommended 3 0 4 7
Refused by patient 0 4 3 7
Unknown/other 1 2 1 4
Total 4 6 8 18
a Causes of No referral in all patients.
b Causes of No treatment in referred-not treated cohort.
TABLE 3. Uptake Patterns Based on Univariate Analyses
Referral Treatmenta
Overall
Uptake
Cofactorsb % pc % pc % pc
Age (yr) 0.019 0.003 0.002
65 59 74 44
65–75 35 50 18
75 27 33 9
Stage 0.001 0.009 0.001
IA 10 0 0
IB 52 54 28
II–III 73 73 54
Surgery type 0.001 0.022 0.001
Wedge 15 0 0
Lobectomy 40 59 24
Pneumonectomy 94 80 75
Health centre 0.006 0.731 0.037
QEII HSC 39 60 24
CBRH 82 55 55
Surgeon 0.087 0.066 0.013
A 44 80 35
B 39 30 12
C 80 75 60
D 37 57 21
MHI ($) 0.049 0.254 0.516
Low (40K) 32 73 23
High (40K) 53 56 30
Distance (km) 0.049 0.749 0.276
Near (32) 54 60 32
Far (32) 33 65 21
a An inverse association between Treatment and “Surgery-Medical Oncology
Consult” elapsed time was also observed (p  0.039).
b Results shown include only those cofactors that predict at least one uptake pattern
at p value 0.05.
c p-values associated with the likelihood ratio by 2 test (2).
MHI, median household income; K, thousands; km, kilometer; PS, performance
status; QEII HSC, Queen Elizabeth II Health Sciences Centre; CBRH, Cape Breton
Regional Hospital.
TABLE 4. Referral Pattern Based on Multifactorial Analysis
Patients
Referred (No.)
Cofactorsa Yes No Odds Ratio 95% CI P-valueb
Age 0.005
Per decade 47 61 2.6 (1.3–5.5)
Stage 0.001
IA 4 38 1.0 —
IB 13 12 14.9 (2.9–76.9)
II–III 30 11 27.4 (5.8–130.7)
Surgery type 0.005
Lobectomy 29 43 1.0 —
Wedge 3 17 0.5 (0.1–2.8)
Pneumonectomy 15 1 40.4 (2.3–705.9)
Surgeon 0.028
A 15 19 1.0 —
B 10 16 0.14 (0.03–0.8)
C 8 2 3.3 (0.3–31.7)
D 14 24 0.7 (0.2–3.1)
MHI 0.015
Low (40 K) 15 32 1.0 —
High (40 K) 32 29 4.7 (1.3–17.8)
MHI, median household income; K, thousands; km, kilometer; No., Number.
a Results shown include only those cofactors that predict Referral pattern at p-value
0.05.
b p-values associated with the likelihood ratio by 2 test (2).
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ity, paucity of data, and possible lack of clear benefit in older
patients who are often excluded from clinical trials because of
associated comorbidities and poorer PS. Treatment decisions
concerning palliative chemotherapy in NSCLC are often
influenced by PS rather than age alone.36 For adjuvant che-
motherapy, a subset analysis of the NCIC BR 10 study36
revealed a significant overall survival benefit with adjuvant
chemotherapy for patients over the age of 65 years (HR 
0.61; 95% CI, 0.38–0.98; p  0.04), which was comparable
to that observed in younger patients, and an acceptable
toxicity. Patients over 75 years of age, however, had a worse
overall survival compared with that of all patients enrolled in
the trial (HR  2.35; 95% CI, 0.84–6.58; p  0.09) though
sample size was too small to draw any firm conclusions in
this elderly age subgroup.
The higher uptake of adjuvant chemotherapy in stage
II–III NSCLC reflects the current evidence which strongly
supports treatment provision in stages II–IIIA disease.25 In
our study, approximately three fourths of patients who un-
derwent surgery for stage II–III NSCLC were referred to MO
and three fourths of those referred were treated (i.e., approx-
imately 50% Overall Uptake). For patients with stage IB
disease, approximately half of patients who underwent sur-
gery were referred and half of those referred were treated
(i.e., approximately 25% Overall Uptake). Currently, the role
of chemotherapy in stage IB disease is less clear,25,26 but a
subset analysis of the CALGB 9633 study suggest that
adjuvant chemotherapy could be considered for stage IB
disease with larger size tumors.23,24 Conversely, there is no
evidence to support platinum based chemotherapy in stage IA
disease and the LACE meta-analysis suggest a potential
detrimental effect in this patient subgroup (HR  1.41; 95%
CI, 0.96–2.09).5 In our study, only 10% of patients with stage
IA disease were referred to MO but none were treated with
adjuvant chemotherapy.
Decision making such as that concerning referral and/or
treatment is complex and involves weighing a number of
variables that are unique to every health care system-provider-
patient encounter. As this study illustrates, uptake patterns
were influenced by a number of variables that are related to
patient (e.g., Age), disease (e.g., Stage or Surgery Type),
practice (e.g., Surgeon or Health Centre), or socioeconomic
status (e.g., MHI). The DFA models we present illustrate the
combined impact of these variables in predicting referral
and/or treatment but the interaction among these variables
may be too complex to allow for identifying exact causes for
FIGURE 2. Discriminant Function Analysis (DFA) Results. A, shows discriminant function (LD1) that best separates patients
referred from those not referred. Patients most likely to be referred had advanced stage (Stage: II/III versus I), were younger
(Age: younger versus older), underwent pneumonectomy (Surgery Type: pneumonectomy versus wedge), treated at the
CBRH (Health Centre: CBRH versus NSCC), or lived in area of higher MHI (MHI: higher versus lower). Factors loadings (relative
magnitude of influence) were as follows: Stage (0.87), Age (0.38), Surgery Type (0.29), Health Centre (0.30), and MHI
(0.29). B, shows discriminant function (LD1) that best separates patients referred and treated from those referred and not
treated. Patients most likely to be treated had advanced stage (Stage: II/III versus I), were younger (Age: younger versus
older), underwent pneumonectomy (Surgery Type: pneumonectomy versus wedge), and experienced shorter “Surgery-MO
Consult” elapsed time (Timeline: shorter versus longer). Factors loadings (relative magnitude of influence) were as follows:
Stage (0.53), Age (0.40), Surgery Type (0.37), and Surgery-MO Consult elapsed time (0.47).
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no referral and/or no treatment. Moreover, studies that assess
uptake of newer interventions should be considered to pro-
vide general predictors of outcomes and should not be simply
regarded as performance measures.
The uptake of adjuvant chemotherapy in NSCLC was
reported in another retrospective study conducted at a single
tertiary center in Ontario, Canada.38 Referral to MO and/or
utilization of chemotherapy during the later period of that
study (June 2004–May 2005) seems comparable to that
observed in our study (January 2005–December 2005); 63%
of all patients were referred to MO and 54% of those referred
were treated (i.e., 34% Overall Uptake). Possible reasons for
not being referred and/or not being treated were retrospec-
tively abstracted from patients’ charts, but statistical analysis
to identify predictors of referral and/or treatment was not
conducted. Reasons for not being referred to MO included;
stage IA disease (37%), patient choice (18%), surgeon rec-
ommendation (15%), significant comorbidities (10%), PO
complications (5%), disease progression (3%), and advanced
age (2%). Reasons for not prescribing adjuvant chemotherapy
included patient refusal (50%), comorbidities (14%), stage IA
disease (10%), disease progression (6%), advanced age (6%),
and unknown (14%).
Our study has limitations. Firstly, the number of cases
meeting the inclusion criteria was relatively small reducing
the overall statistical power of the study and limiting the
stability of weak associations. However, we employed both
multifactorial and discriminant function analyses and the
results were almost identical. Secondly and perhaps more
importantly, the retrospective nature of our study did not
allow us to determine the exact causes of no referral and/or no
treatment. However, the predictors of referral and/or treat-
ment identified may help improve future chemotherapy up-
take rates. Thirdly, our study examined the uptake patterns in
the first year (i.e., 2005) after adjuvant chemotherapy for
NSCLC was accepted as a new standard of care. It is possible
that uptake patterns may have changed since then, as further
updated data from clinical trials were reported, and/or mature
studies were fully published.
In summary, approximately one third of patients who
underwent curative-intent surgery for NSCLC were treated
with adjuvant chemotherapy. Consistent with other reports in
breast and colorectal cancers, higher uptake of adjuvant
chemotherapy was observed in younger patients and those
with more advanced disease stages. Improved referral to MO
may increase the overall uptake of adjuvant chemotherapy as
a high proportion of those referred were treated. Prospective
assessment, however, is still required to better determine the
exact causes of no referral and/or no treatment in clinical
decision making that is unique to every health care system-
provider-patient encounter. In the interim, the uptake patterns
observed in this study may help future planning of health
resource utilization and/or improvement of chemotherapy
uptake rates.
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